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Abstract 
Background: Malaria eradication globally is yet to be achieved and transmission is sustained in many endemic coun-
tries. Plasmodium falciparum continues to develop resistance to currently available anti-malarial drugs, posing great 
problems for malaria elimination. This study evaluates the frequencies of asymptomatic infection and multidrug resist-
ance-1 (mdr-1) gene mutations in parasite isolates, which form the basis for understanding persistently high incidence 
in South West, Nigeria.
Methods: A total of 535 individuals aged from 6 months were screened during the epidemiological survey evaluat-
ing asymptomatic transmission. Parasite prevalence was determined by histidine-rich protein II rapid detection kit 
(RDT) in healthy individuals. Plasmodium falciparum mdr-1 gene mutations were detected by polymerase chain reac-
tion (PCR) followed by restriction enzyme digest and electrophoresis to determine polymorphism in parasite isolates. 
Sequencing was done to confirm polymorphism. Proportions were compared using Chi-square test at p value < 0.05.
Results: Malaria parasites were detected by RDT in 204 (38.1%) individuals. Asymptomatic infection was detected 
in 117 (57.3%) and symptomatic malaria confirmed in 87 individuals (42.6%). Overall, individuals with detectable 
malaria by RDT was significantly higher in individuals with symptoms, 87 of 197 (44.2%), than asymptomatic persons; 
117 of 338 (34.6%), p = 0.02. In a sub-set of 75 isolates, 18(24%) and 14 (18.6%) individuals had Pfmdr1 86Y and 1246Y 
mutations.
Conclusions: There is still high malaria transmission rate in Nigeria with higher incidence of asymptomatic infections. 
These parasites harbour mutations on Pfmdr1 which contribute to artemisinin partner drug resistance; surveillance 
strategies to reduce the spread of drug resistance in endemic areas are needed to eliminate the reservoir of malaria 
parasites that can mitigate the eradication of malaria in Nigeria.
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Background
Malaria prevalence has declined to about 216 million 
cases estimated in 2016 but progress in malaria reduc-
tion appears to be stagnant as reported in the World 
Malaria Report 2018 with the highest transmission 
rates still recorded in the African region [1]. Increasing 
drug resistance in Plasmodium falciparum in South-
east Asia and Africa now mitigates the use of some 
available artemisinin combination drugs for effective 
malaria eradication [1, 2]. In Nigeria, malaria transmis-
sion remains high, in South West area of Nigeria, malaria 
is highly endemic and transmission occurs all year 
round, however prevalence of malaria is often underes-
timated because sub-microscopic malaria is common 
[3]. Chemoprevention strategies for eradicating malaria, 
such as mass drug administration with primaquine to 
reduce the high reservoir of malaria infection, cannot 
be implemented in most malaria-endemic countries due 
to drug resistance and potential prevalence of glucose-
6-phosphate deficiency (G6PD) [3–8]. Several studies 
from malaria endemic countries have reported single 
nucleotide polymorphisms (SNPs), including K76T on 
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P. falciparum chloroquine resistance transporter gene 
(Pfcrt); N86Y, S1034C, Y184F, N1042D, and D1246Y 
SNPs on multidrug resistance gene 1 (Pfmdr1) and other 
loci, which confers resistance to artemisinin and its part-
ner drugs, such as chloroquine, quinine, amodiaquine, 
lumefantrine, and piperaquine [9–21].
Monitoring the prevalence of these molecular mark-
ers of resistance plays a significant role in assessing 
effective malaria chemotherapy for reducing malaria 
intensities. To curb the spread of drug resistance and 
for effective malaria control, it is necessary to study the 
genetic backgrounds of parasite isolates that circulate 
in asymptomatic infections, which are often exposed to 
sub-therapeutic doses of anti-malarial drugs, as these 
polymorphisms alter parasite susceptibility to arte-
misinin combination treatment (ACT) [1]. This study 
aims to determine frequencies of Pfmdr1 mutations in 
parasite isolates and intensities of asymptomatic malaria 
transmission in an endemic area of Nigeria.
Methods
The study was carried out in Ota, South West Nigeria to 
evaluate asymptomatic malaria incidence and molecular 
markers of anti-malarial drug resistance in P. falciparum. 
Persons aged > 6 months, without any symptoms sugges-
tive of malaria at the time malaria test was done and in 
persons reporting a history of fever within the previous 
2 weeks participated in the community health screening 
for malaria prevalence and were included in the study 
which took place at intervals from April to May and 
November to December (both in dry and wet seasons) 
around communities in Ota, Ogun State in 2018. The 
participants gave informed consent and the study was 
approved by Covenant Health Research Ethics Commit-
tee (approval number: CHREC/010/2018). Parasite preva-
lence was determined by histidine-rich protein II-based 
rapid test kit. The minimum sample size required for the 
study was calculated as 384, using an estimated popula-
tion of 527,242 persons living in Ota and a 5% margin of 
error. Molecular analysis was done at Molecular Biology 
Laboratory of Covenant University. Blood from posi-
tive samples were used for PCR analysis. Genomic DNA 
was extracted using Aidlab Blood & Tissue DNA mini kit 
according to the manufacturer’s instruction and primers 
flanking codon 86 and 1246 of Pfmdr1 gene was used [22]. 
PCR amplification was done on C1000 Touch™ Ther-
mal Cycler (Bio-Rad Laboratories Inc., USA) using PCR 
super-mix (New England Biolabs, USA). Table  1 shows 
the details of primers and PCR conditions used. Nested 
PCR products were restricted by enzymatic digest with 
specific restriction enzymes: AflIII (New England Biolabs, 
USA) was used to detect mutation causing base change 
from asparagine (N) to tyrosine (Y) at codon 86 while 
EcoRV (Beijing TransGen Biotech, China) was used to 
detect mutation causing base change from aspartic acid 
(D) to tyrosine (N) at codon 1246. Enzyme was incubated 
at 37 °C for 1 h and inactivated at 65 °C for 20 min, 10 µl 
of the digested product was resolved on 2% agarose gel 
and sized against molecular weight marker. To confirm 
mutation, 15   µl of amplicons were sent for sequencing 
(Inqaba Biotec West Africa Ltd, South Africa). Sequence 
alignment with reference 3D7 strain (PF3D7_0523000) 
was carried out using Geneious software® version 11.6. 
The data was analysed using SPSS software version 16 
(SPSS Inc., Chicago, USA). Proportions were compared 
using Chi-square test at significant level of p < 0.05.
Results
Transmission intensities
During the study period, 535 blood samples were exam-
ined for the presence of P. falciparum infections by RDT. 
Malaria was detected in 204 (38.1%) blood samples; 87 
(42.6%) infections in symptomatic carriers while 117 
(57.3%) persons were asymptomatic. Overall the pro-
portion of individuals with detectable malaria by RDT 
(positivity rate) was significantly higher in those with 
symptoms (87 of 197, 44.2%) than asymptomatic per-
sons (117 of 338, 34.6%), χ2 = 4.80, p = 0.02. Based on age, 
overall malaria incidence was 7 of 49 (14.2%), 81 of 143 
(56.6%), 60 of 195 (30.7%) and 56 of 148 (37.85) in age 
Table 1 Primer sequence of Pfmdr1 gene flanking at codon 86 and 1246
Primer Sequence (5′ → 3′) Direction PCR 
product 
(bp)
Cycling condition
Pfmdr1 86 and 184 AGA GAA AAA AGA TGG TAA CCT CAG Forward 590 95 °C for 3 min, 34 cycles of 95 °C for 45 s, 60.2 °C for 45 s, and 
72 °C for 5 minACC ACA AAC ATA AAT TAA CGG Reverse
Pfmdr1 1246 GTG GAA AAT CAA CTT TTA TGA Forward 499 94 °C for 5 min, 35 cycles of 94 °C for 1 min, 53 °C for 1 min, 72 °C 
for 1 minTTA GGT TCT CTT AAT AAT GCT Reverse
GAC TTG AAA AAT GAT CAC ATT Forward nested 409 94 °C for 5 min, 35 cycles of 94 °C for 1 min, 50 °C for 1 min, 72 °C 
for 1 minGTC CAC CTG ATA AGC TTT T Reverse nested
Page 3 of 7Dokunmu et al. Malar J          (2019) 18:218 
groups < 2, > 2–10, > 10–18, and > 18  years, respectively. 
Similarly, asymptomatic infection was detected in 0 of 
49 (0%), 9 of 143 (6%), 54 of 195 (27.6%), and 54 of 148 
(36.4%) in age groups < 2, > 2–10, > 10–18, and > 18 years, 
respectively. Malaria incidence was highest in children 
aged > 2–10  years, however asymptomatic infection was 
higher in older children and adults (p < 0.0001). There 
was no difference in prevalence between different gen-
ders. Of the 204 positive samples, 75 randomly selected 
samples were evaluated for the presence of Pfmdr1 muta-
tions. Figure 1 shows the flow chart for the study.
Pfmdr1 mutations
Seventy-five positive samples selected from asympto-
matic and symptomatic infections were evaluated for 
Pfmdr1 mutations at codons 86 and 1246. In 18 of 75 
(24%) isolates, 86Y alleles were detected. Similarly, 14 
of 75 (18.6%) isolates had 1246Y mutant alleles, Fig.  2 
(χ2 = 0.63, p = 0.42). Of the total, 9 isolates (12%) had 
both 86Y and 1246Y mutant alleles (Fig. 3). The propor-
tions in asymptomatic and symptomatic infections were 
similar. To confirm restriction fragment length polymor-
phism (RFLP) digest, sequencing of few isolates with 
mutant 86Y allele aligned with 3D7 reference strain fur-
ther confirms amino acid substitution from asparagine 
(N) to tyrosine (Y) (Fig. 4).
Discussion
Malaria has persisted for several decades due to devel-
opment of resistance to available anti-malarial drugs, 
including artemisinin derivatives and its partner drugs, 
and unbroken transmission in highly endemic coun-
tries [1, 2]. To achieve malaria elimination especially 
in endemic areas, reducing the pool of infection by 
asymptomatic carriers, scaling up of control measures 
such as chemoprevention, vector control and monitor-
ing of resistance for effective treatment are all essential 
to break transmission [23, 24], which has been achieved 
535 persons screened
204 posive for malaria
117 with asymptomac 
infecon 
35 analysed for Pfmdr 1
mutaons
87 with symptomac 
infecon 
40 analysed for Pfmdr 1
mutaons 
331 negave for 
malaria 
Fig. 1 Flow chart for the study
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Fig. 2 Prevalence of mutant alleles detected at codon 86 (24%) and 
1246 (19%) of Pfmdr 1 gene in parasite isolates during the study
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in some countries [1, 2]. World Health Organization 
reported stalled progress in malaria reduction from 
2015 to 2017 especially from the African region. Nige-
ria alone contributes 25%, the highest proportion borne 
by any single country to malaria burden globally, while 
other African countries, such as Democratic Republic 
of Congo (11%) and Mozambique (5%) follow [2].
Asymptomatic infection is common in endemic 
areas [3–7], and wide epidemiological surveys utiliz-
ing PCR are very valuable to estimate the true burden 
in endemic areas for planning effective malaria control 
strategies. Parasites isolated in untreated infections 
can harbour resistant genes as a tool for survival; this 
study reports the presence of Pfmdr1  86Y (confirmed 
by sequencing) and 1246Y mutant alleles being trans-
mitted in asymptomatic as well as symptomatic infec-
tions. This finding is similar to reports from endemic 
and non-endemic areas where Pfmdr1 has served as 
a molecular marker of detecting anti-malarial drug 
resistance [13, 14, 16, 21]. Most malaria-endemic coun-
tries are in the pre-elimination phase because local 
transmission is still high [2]. This is largely because 
malaria parasites may be harboured by persons who 
show no symptoms; consequently, long term carriage 
of asymptomatic infections promotes development of 
committed gametocytes, and these are picked up by 
mosquito, increasing malaria transmission.
This cycle of asymptomatic transmission is unhindered 
in a country such as Nigeria because of the lack of pro-
phylactic chemoprevention which is not encouraged due 
to drug resistance in the area [25]. The current study 
and previously reported studies clearly demonstrate that 
asymptomatic malaria infection is very common [3–7] in 
Nigeria and other endemic countries. However, clearance 
of these parasite reservoirs by mass drug administration 
using a slowly eliminated drug and tissue schizonticide 
such as primaquine cannot be explored because of the 
limitations of drug-induced haemolysis in some regions. 
Reflecting on prevalence of Plasmodium falciparum 
rates over time in Nigeria to date, it can be surmised that 
transmission has not significantly declined if epidemio-
logical screenings are regularly done; a rate of 57% was 
detected in this study which is not similar to other recent 
studies [26] or previous studies in Nigeria [27–29].
With this trend in other parts of Africa [30], the agenda 
to eliminate malaria, which aims to completely remove 
and eradicate the disease locally and globally, can be 
achieved but through elimination of circulating para-
site reservoir (infection from asymptomatic persons to 
mosquito and to new host), a crucial step for moving 
endemic countries out of the pre-elimination phase. Fac-
tors that favour intense transmission, including parasite 
reservoir, competent vectors and suitable breeding sites 
and climatic conditions, are predominant in Africa; a 
Fig. 3 Restriction digest product for Pfmdr1 SNP detection at codon 86 (a) and 1246 (b)
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multifaceted approach to curtail transmission through all 
these influential factors should be promoted.
In asymptomatic infections, a similar proportion of 
86Y and 1246Y mutant alleles was present as in symp-
tomatic infections. Asymptomatic parasite tolerance 
is determined by the host immunity, hence the higher 
proportions in adults older than 18  years. Higher 
prevalence of these mutations conferring resistance to 
chloroquine, artemether, mefloquine was previously 
reported in Nigeria [11, 12, 15, 16], but the findings, 
similar to a recent study from northern Nigeria [26], 
indicate a decline in the prevalence of mutations. 
Therefore, determining the prevalence of these molecu-
lar markers can be used to assess the degree of trans-
mission and the impact of prophylactic chemotherapy 
for malaria control in Nigeria.
Mutations on the Pfmdr1 gene play a pivotal role with 
variable parasite response to artemisinin, ACT and non-
ACT, such as chloroquine, lumefantrine, primaquine, 
tafenoquine, piperaquine, and mefloquine [31–38], due 
Fig. 4 Screenshot of alignment of Pfmdr1 gene flanking codon 86 in 2 isolates (with mutant allele- tyrosine) compared to reference 3D7 strain 
(sensitive allele-asparagine)
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to conformational changes in the transporter protein 
causing decrease in intracellular drug accumulation 
and effect on the malaria parasite.The haplotype N86Y-
Y184F-D1246Y of Pfmdr1 was reported to be susceptible 
to artemisinin-based combination, whereas triple muta-
tions S1034C, N1042D and D1246Y or increased gene 
copy number are associated with parasite resistance to 
mefloquine, halofantrine and artemisinin [36]. Although 
this study did not assess Pfcrt mutation, there is known 
synergy between mutations on Pfmdr1 and Pfcrt genes 
[39]. Studies in Nigeria and other areas have reported 
reduced in  vitro and in  vivo response in chloroquine-
resistant isolates bearing the 76T mutation correlating 
strongly with Pfmdr1 86Y mutation [12, 14, 16, 21, 22, 
38].
Although molecular markers alone may not connote 
resistance except resulting in drug failure, it however can 
predict the potential of parasites to develop drug resist-
ance [9, 11, 12]. By implication, frequency of Pfmdr1 
mutations observed in this area is low, but malaria inci-
dence has not decreased significantly. Including asympto-
matic malaria control using combinations not previously 
used [40], e.g., pyronaridine-artemisinin for chemopro-
phylaxis in persons with malaria infections, should be 
considered for Nigeria to clear out circulating asympto-
matic infections for complete elimination of parasite res-
ervoir. Evidence from the study shows one in six parasite 
isolates bear mutant 86Y and 1246Y alleles; eliminating 
these with effective drugs, together with high asympto-
matic parasitaemia will greatly impact malaria eradica-
tion in this endemic area.
Limitations of this study were that microscopy, the gold 
standard, was not used for estimating malaria prevalence 
and follow-up was not done to determine if asympto-
matic individuals eventually became symptomatic. Sec-
ondly, histidine-rich protein II RDTs may have detected 
malaria antigens in recently cleared infection, and RDTs 
may not detect infections at very low densities in some 
individuals [41, 42]. Future studies evaluating asymp-
tomatic malaria prevalence with PCR methods are 
recommended.
Conclusion
There is a high malaria transmission rate in Nigeria with 
higher incidence of asymptomatic infections. These para-
sites harbour mutations on Pfmdr1, which contribute to 
artemisinin partner drug resistance; surveillance strate-
gies to reduce the spread of drug resistance in endemic 
areas are needed to eliminate the reservoir of malaria 
parasites that can mitigate the eradication of malaria in 
Nigeria.
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